CD274 and non-small cell lung carcinoma: The randomized phase II study (POPLAR) observed that atezolizumab met its primary endpoint and showed a statistically significant survival benefit compared to docetaxel (HR = 0.54; p = 0.014) in people with recurrent NSCLC whose tumors expressed medium and high levels of PD-L1 expression [40].